AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie lupron (leuprolide) [legacy through FY21] — U.S. net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q4 2021
148
Period ended Dec 31, 2021
Change on a year earlier
+6.5%
139 in Q4 2020
History
20 quarters
Since Q1 2017
Sources
15
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lupron (leuprolide) [legacy through FY21] — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2021 | Dec 31, 2021 | 148 | +6.5% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2021 | Sep 30, 2021 | 134 | +35.4% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 151 | -9.6% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 171 | -12.3% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 139 | -20.1% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2020 | Sep 30, 2020 | 99 | -47.1% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2020 | Jun 30, 2020 | 167 | -0.6% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2020 | Mar 31, 2020 | 195 | +2.1% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 174 | -11.2% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2019 | Sep 30, 2019 | 187 | +8.1% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2019 | Jun 30, 2019 | 168 | -6.7% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2019 | Mar 31, 2019 | 191 | +7.9% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 196 | +8.3% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2018 | Sep 30, 2018 | 173 | +7.5% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 180 | +4.7% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 177 | +14.2% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 181 | – | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2017 | Sep 30, 2017 | 161 | – | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 172 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 155 | – | Form 10-Q (filed 2018-05-04) ↗ |
Breakdown
What makes up lupron (leuprolide) [legacy through fy21] — u.s. net revenues ($m)
Cite this data
StockData. (2026). AbbVie Lupron (leuprolide) [legacy through FY21] — U.S. net revenues ($M) ($M), quarterly Q1 2017–Q4 2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lupron_us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.